细胞淋巴瘤-话题@MedSci

#细胞淋巴瘤#

385篇内容 | 5192人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1702728, encodeId=5ba01e0272897, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Cancer Treat Rev：弥漫大B细胞淋巴瘤的治疗策略, objectType=article, longId=737986, objectId=a974e379869c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a974e379869c, replyNumber=0, likeNumber=152, createdTime=2023-01-22, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a974e379869c, moduleTitle=Cancer Treat Rev：弥漫大B细胞淋巴瘤的治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a974e379869c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702730, encodeId=98cf1e0273000, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, objectType=article, longId=739079, objectId=dbbfe390796d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbbfe390796d, replyNumber=0, likeNumber=107, createdTime=2023-02-17, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbbfe390796d, moduleTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbbfe390796d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702718, encodeId=d4491e02718ed, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=血液肿瘤3天训练营 | Day 3 : 套细胞淋巴瘤的研究进展与未来展望, objectType=article, longId=730238, objectId=739ee30238b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=739ee30238b6, replyNumber=0, likeNumber=88, createdTime=2022-11-14, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=739ee30238b6, moduleTitle=血液肿瘤3天训练营 | Day 3 : 套细胞淋巴瘤的研究进展与未来展望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=739ee30238b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702720, encodeId=0c501e02720b6, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Clin Cancer Res：来那度胺联合R-GDP治疗复发/难治性弥漫性大B细胞淋巴瘤, objectType=article, longId=730251, objectId=bec7e302514e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec7e302514e, replyNumber=0, likeNumber=116, createdTime=2023-04-15, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec7e302514e, moduleTitle=Clin Cancer Res：来那度胺联合R-GDP治疗复发/难治性弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bec7e302514e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702726, encodeId=b8ec1e02726f7, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=J Clin Oncol：利妥昔单抗+来那度胺+依鲁替尼治疗新诊断的弥漫性大B细胞淋巴瘤, objectType=article, longId=735739, objectId=d3ece357396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3ece357396e, replyNumber=0, likeNumber=131, createdTime=2023-04-22, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3ece357396e, moduleTitle=J Clin Oncol：利妥昔单抗+来那度胺+依鲁替尼治疗新诊断的弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3ece357396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702714, encodeId=69481e0271428, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Leukemia：Guadecitabine（SGI-110）在外周T细胞淋巴瘤中的综合临床评估, objectType=article, longId=726160, objectId=eab4e261604e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eab4e261604e, replyNumber=0, likeNumber=96, createdTime=2022-12-16, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eab4e261604e, moduleTitle=Leukemia：Guadecitabine（SGI-110）在外周T细胞淋巴瘤中的综合临床评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eab4e261604e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702724, encodeId=00431e0272458, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet Oncol：Lisocabtagene maraleucel二线治疗难治性/复发性大B细胞淋巴瘤, objectType=article, longId=732664, objectId=82c1e326649a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c1e326649a, replyNumber=0, likeNumber=126, createdTime=2022-12-01, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c1e326649a, moduleTitle=Lancet Oncol：Lisocabtagene maraleucel二线治疗难治性/复发性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c1e326649a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702711, encodeId=74981e027119e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=JEADV：皮肤T细胞淋巴瘤的肠道菌群失调的特征研究, objectType=article, longId=724096, objectId=ba7be240966c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba7be240966c, replyNumber=0, likeNumber=221, createdTime=2022-09-12, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba7be240966c, moduleTitle=JEADV：皮肤T细胞淋巴瘤的肠道菌群失调的特征研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba7be240966c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702729, encodeId=6e151e02729b7, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【Nat Med】肿瘤免疫微环境在大B细胞淋巴瘤CAR T治疗中具有决定性作用, objectType=article, longId=738108, objectId=602be38108fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=602be38108fe, replyNumber=0, likeNumber=115, createdTime=2023-05-04, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=602be38108fe, moduleTitle=【Nat Med】肿瘤免疫微环境在大B细胞淋巴瘤CAR T治疗中具有决定性作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=602be38108fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702717, encodeId=da1a1e02717c5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet：Liso-cel vs 标准疗法二线治疗原发难治性/早期复发性大B细胞淋巴瘤, objectType=article, longId=730182, objectId=b81ce30182de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b81ce30182de, replyNumber=0, likeNumber=115, createdTime=2023-02-19, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b81ce30182de, moduleTitle=Lancet：Liso-cel vs 标准疗法二线治疗原发难治性/早期复发性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b81ce30182de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702707, encodeId=65161e027077e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NEJM：Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的效果如何？, objectType=article, longId=298992, objectId=90c929899271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90c929899271, replyNumber=0, likeNumber=135, createdTime=2022-03-12, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90c929899271, moduleTitle=NEJM：Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90c929899271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702721, encodeId=da331e0272148, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Hematol Oncol：诊断为弥漫性大 B 细胞淋巴瘤并接受蒽环类药物治疗的患者心血管事件和死亡率的危险因素, objectType=article, longId=731395, objectId=ba22e3139533, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba22e3139533, replyNumber=0, likeNumber=114, createdTime=2023-02-04, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba22e3139533, moduleTitle=Hematol Oncol：诊断为弥漫性大 B 细胞淋巴瘤并接受蒽环类药物治疗的患者心血管事件和死亡率的危险因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba22e3139533)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702716, encodeId=a4491e02716f5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=J Clin Oncol：采用KTE-X19治疗复发/难治性套细胞淋巴瘤的3年随访结果, objectType=article, longId=728874, objectId=d52ae288743f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d52ae288743f, replyNumber=0, likeNumber=101, createdTime=2022-10-31, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d52ae288743f, moduleTitle=J Clin Oncol：采用KTE-X19治疗复发/难治性套细胞淋巴瘤的3年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d52ae288743f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702725, encodeId=dad01e0272593, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【Blood Adv】利妥昔单抗时代低级别B细胞淋巴瘤的死亡原因分析-来自一项前瞻性队列研究, objectType=article, longId=734612, objectId=dddce3461202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dddce3461202, replyNumber=0, likeNumber=148, createdTime=2022-11-09, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dddce3461202, moduleTitle=【Blood Adv】利妥昔单抗时代低级别B细胞淋巴瘤的死亡原因分析-来自一项前瞻性队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dddce3461202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702704, encodeId=46ab1e02704c3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle= Blood：采用JAK/STAT抑制剂鲁索替尼治疗T细胞淋巴瘤, objectType=article, longId=295178, objectId=3c1e2951e899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c1e2951e899, replyNumber=0, likeNumber=115, createdTime=2022-10-04, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c1e2951e899, moduleTitle= Blood：采用JAK/STAT抑制剂鲁索替尼治疗T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c1e2951e899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702695, encodeId=04c91e0269520, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Ann Hematol：基于POV的补救免疫化疗作为弥漫性大 B 细胞淋巴瘤患者的三线或以上治疗, objectType=article, longId=221086, objectId=28ac2210860c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ac2210860c, replyNumber=0, likeNumber=98, createdTime=2022-01-01, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ac2210860c, moduleTitle=Ann Hematol：基于POV的补救免疫化疗作为弥漫性大 B 细胞淋巴瘤患者的三线或以上治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ac2210860c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702697, encodeId=67c81e026979d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=AJH：B 细胞淋巴瘤患者的异源 SARS-CoV-2 疫苗接种, objectType=article, longId=221143, objectId=43d122114320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43d122114320, replyNumber=0, likeNumber=97, createdTime=2022-03-05, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43d122114320, moduleTitle=AJH：B 细胞淋巴瘤患者的异源 SARS-CoV-2 疫苗接种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43d122114320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702727, encodeId=89e91e027273e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：CAR T细胞治疗大B细胞淋巴瘤的真实临床数据分析, objectType=article, longId=736335, objectId=0832e3633554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0832e3633554, replyNumber=0, likeNumber=141, createdTime=2022-10-30, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0832e3633554, moduleTitle=Blood：CAR T细胞治疗大B细胞淋巴瘤的真实临床数据分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0832e3633554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702722, encodeId=de4d1e027228e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【新英格兰医学杂志】套细胞淋巴瘤综述（全文翻译）, objectType=article, longId=731538, objectId=0864e3153864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0864e3153864, replyNumber=0, likeNumber=120, createdTime=2023-06-07, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0864e3153864, moduleTitle=【新英格兰医学杂志】套细胞淋巴瘤综述（全文翻译）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0864e3153864)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702703, encodeId=ebb11e02703c8, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, objectType=article, longId=295064, objectId=3d5529506462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d5529506462, replyNumber=0, likeNumber=116, createdTime=2022-06-05, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d5529506462, moduleTitle=Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d5529506462)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞淋巴瘤

2020-05-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Cancer Treat Rev：弥漫大B细胞淋巴瘤的治疗策略

2023-01-22

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）

2023-02-17

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

血液肿瘤3天训练营 | Day 3 : 套细胞淋巴瘤的研究进展与未来展望

2022-11-14

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Clin Cancer Res：来那度胺联合R-GDP治疗复发/难治性弥漫性大B细胞淋巴瘤

2023-04-15

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

J Clin Oncol：利妥昔单抗+来那度胺+依鲁替尼治疗新诊断的弥漫性大B细胞淋巴瘤

2023-04-22

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Leukemia：Guadecitabine（SGI-110）在外周T细胞淋巴瘤中的综合临床评估

2022-12-16

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet Oncol：Lisocabtagene maraleucel二线治疗难治性/复发性大B细胞淋巴瘤

2022-12-01

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

JEADV：皮肤T细胞淋巴瘤的肠道菌群失调的特征研究

2022-09-12

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【Nat Med】肿瘤免疫微环境在大B细胞淋巴瘤CAR T治疗中具有决定性作用

2023-05-04

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet：Liso-cel vs 标准疗法二线治疗原发难治性/早期复发性大B细胞淋巴瘤

2023-02-19

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NEJM：Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的效果如何？

2022-03-12

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Hematol Oncol：诊断为弥漫性大 B 细胞淋巴瘤并接受蒽环类药物治疗的患者心血管事件和死亡率的危险因素

2023-02-04

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

J Clin Oncol：采用KTE-X19治疗复发/难治性套细胞淋巴瘤的3年随访结果

2022-10-31

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【Blood Adv】利妥昔单抗时代低级别B细胞淋巴瘤的死亡原因分析-来自一项前瞻性队列研究

2022-11-09

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：采用JAK/STAT抑制剂鲁索替尼治疗T细胞淋巴瘤

2022-10-04

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Ann Hematol：基于POV的补救免疫化疗作为弥漫性大 B 细胞淋巴瘤患者的三线或以上治疗

2022-01-01

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

AJH：B 细胞淋巴瘤患者的异源 SARS-CoV-2 疫苗接种

2022-03-05

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：CAR T细胞治疗大B细胞淋巴瘤的真实临床数据分析

2022-10-30

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【新英格兰医学杂志】套细胞淋巴瘤综述（全文翻译）

2023-06-07

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程

2022-06-05

科室
- - 订阅+
  - 更多科室
工具
服务